The sequence-specific binding of cisplatin (cis-diamminedichloroplatinum(II)) to DNA appears to be responsible for its antitumor activity. The drug preferentially binds to Guanine bases and can introduce intrastrand crosslinks at dGdG, dGdXdG and dAdG sequences, whereas interstrand crosslinking can occur at dGdC-steps.